ES2246829T3 - Inhibidores purinicos de cinasa 2 y de ikb-alfa dependientes de ciclina. - Google Patents

Inhibidores purinicos de cinasa 2 y de ikb-alfa dependientes de ciclina.

Info

Publication number
ES2246829T3
ES2246829T3 ES00908325T ES00908325T ES2246829T3 ES 2246829 T3 ES2246829 T3 ES 2246829T3 ES 00908325 T ES00908325 T ES 00908325T ES 00908325 T ES00908325 T ES 00908325T ES 2246829 T3 ES2246829 T3 ES 2246829T3
Authority
ES
Spain
Prior art keywords
cinasa
purinic
cycline
dependents
ikb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00908325T
Other languages
English (en)
Inventor
Robert T Lum
Cheri Lynn Blum
Richard Mackman
Michael M Wick
Steven R Schow
Jeffery A Zablocki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Application granted granted Critical
Publication of ES2246829T3 publication Critical patent/ES2246829T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuesto seleccionado de entre el grupo constituido por: {2-[(2-aminoetil)amino]-9-(metiletil)purin-6- il}[{4-clorofenil}metil]amina; {2-[(2-aminopropil)amino]-9-(metiletil)purin-6- il}[(4-clorofenil)metil]amina; {2-[(2-aminoetil)(6-{[(4- clorofenil)metil]amino}-9-(metiletil)purin-2- il)amino]etan-1-ol; y 2-[(2-hidroxietil)(6-{[(4- clorofenil)metil]amino}-9-(metiletil)purin-2- il)amino]etan-1-ol.
ES00908325T 1999-02-01 2000-01-20 Inhibidores purinicos de cinasa 2 y de ikb-alfa dependientes de ciclina. Expired - Lifetime ES2246829T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24122499A 1999-02-01 1999-02-01

Publications (1)

Publication Number Publication Date
ES2246829T3 true ES2246829T3 (es) 2006-03-01

Family

ID=22909777

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00908325T Expired - Lifetime ES2246829T3 (es) 1999-02-01 2000-01-20 Inhibidores purinicos de cinasa 2 y de ikb-alfa dependientes de ciclina.

Country Status (26)

Country Link
EP (1) EP1150982B1 (es)
JP (1) JP3681984B2 (es)
KR (1) KR20010093308A (es)
CN (1) CN1353713A (es)
AR (1) AR029612A1 (es)
AT (1) ATE306487T1 (es)
AU (1) AU2969300A (es)
BR (1) BR0007919A (es)
CA (1) CA2361518A1 (es)
CZ (1) CZ20012765A3 (es)
DE (1) DE60023268T2 (es)
DK (1) DK1150982T3 (es)
ES (1) ES2246829T3 (es)
GE (1) GEP20033092B (es)
HK (1) HK1044334A1 (es)
HU (1) HUP0200535A3 (es)
IL (2) IL144675A0 (es)
MX (1) MXPA01007851A (es)
NO (1) NO327776B1 (es)
NZ (1) NZ513371A (es)
PL (1) PL350001A1 (es)
RU (1) RU2001124352A (es)
TR (1) TR200102714T2 (es)
TW (1) TW538044B (es)
UA (1) UA74142C2 (es)
WO (1) WO2000044750A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
DE69932828T2 (de) 1998-08-29 2007-10-18 Astrazeneca Ab Pyrimidine verbindungen
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
CA2394654A1 (en) 1999-12-17 2001-06-21 Manfred Weigele Proton pump inhibitors
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
WO2003002565A1 (en) * 2001-06-27 2003-01-09 Cyclacel Limited 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders
EP2336133A1 (en) 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US7189730B2 (en) 2001-12-18 2007-03-13 Cv Therapeutics, Inc. A2A adenosine receptor antagonists
ES2276084T3 (es) 2002-02-15 2007-06-16 Cv Therapeutics, Inc. Revestimiento polimerico para dispositivos medicos.
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
JP2005524672A (ja) 2002-03-09 2005-08-18 アストラゼネカ アクチボラグ Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US7476670B2 (en) 2003-02-18 2009-01-13 Aventis Pharma S.A. Purine derivatives, method for preparing, pharmaceutical compositions and novel use
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
EP2145888A1 (en) 2003-09-18 2010-01-20 Conforma Therapeutics Corporation Deazapurine derivatives as HSP90-Inhibitors
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
FR2880626B1 (fr) * 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
BRPI0609509A2 (pt) 2005-03-30 2010-04-13 Conforma Therapeutics Corp composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável
EP1881987B1 (en) * 2005-05-16 2016-10-19 Prometic Pharma Smt Limited Purine derivatives and their use for treatment of autoimmune diseases
CA2601869A1 (en) * 2005-08-12 2007-02-22 Astellas Pharma Inc. Method for identifying target protein of agent and method for screening therapeutic agent for diabetes using target protein
BRPI0616722A2 (pt) 2005-09-30 2012-12-25 Astrazeneca Ab composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, e, mÉtodos para produzir um efeito anti-proliferaÇço celular e um efeito inibidor cdk2, para tratar cÂncer, e para tratar doenÇas
GB0706632D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR102030609B1 (ko) 2011-09-02 2019-10-11 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
MD20140023A2 (ro) 2011-09-22 2014-06-30 Pfizer Inc. Derivaţi de pirolpirimidină şi purină
WO2013130461A1 (en) 2012-02-29 2013-09-06 The Scripps Research Institute Wee1 degradation inhibitors
EP2634190A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CZ306894B6 (cs) * 2013-02-08 2017-08-30 Univerzita PalackĂ©ho v Olomouci 2-Substituované-6-biarylmethylamino-9-cyklopentyl-9H-purinové deriváty, jejich použití jako léčiva a farmaceutické přípravky tyto sloučeniny obsahující
WO2014134750A1 (zh) * 2013-03-08 2014-09-12 中国人民解放军军事医学科学院放射与辐射医学研究所 2,6,9-三取代嘌呤衍生物及其制备方法与应用
WO2015005491A1 (ja) * 2013-07-12 2015-01-15 国立大学法人京都大学 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法
FR3011240A1 (fr) * 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
DK3831833T3 (da) 2015-02-27 2022-11-14 Incyte Holdings Corp Fremgangsmåder til fremstillingen af en pi3k-inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN107235981B (zh) * 2017-05-25 2019-10-25 北京工业大学 低氧激活o6-苄基-2-硝基嘌呤衍生物及制法和应用
CN107903274A (zh) * 2017-12-28 2018-04-13 窦玉玲 一种胺类化合物及其在抗肿瘤药物中的应用
CN119258070A (zh) 2018-06-01 2025-01-07 因赛特公司 治疗pi3k相关病症的给药方案
CN110256436B (zh) * 2019-06-27 2020-06-09 南京雷正医药科技有限公司 作为Trk激酶抑制剂的嘌呤类化合物
ES2987269T3 (es) * 2019-09-20 2024-11-14 Novartis Ag Inhibidores de MLL1 y agentes anticancerígenos
CN117479944A (zh) * 2021-04-02 2024-01-30 泰州亿腾景昂药业股份有限公司 周期蛋白依赖性激酶抑制剂
JP7770065B2 (ja) * 2021-08-11 2025-11-14 タイチョウ イーオーシー ファーマ カンパニー リミテッド サイクリン依存性キナーゼ阻害剤
WO2023046128A1 (en) * 2021-09-27 2023-03-30 Taizhou Eoc Pharma Co., Ltd. A cyclin-dependent kinase inhibitor
AU2023393410A1 (en) 2022-12-16 2025-07-31 Astrazeneca Ab 2,6,9-trisubstituted purines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6255485B1 (en) * 1997-08-07 2001-07-03 The Regents Of The University Of California Purine inhibitors of protein kinases, G proteins and polymerases

Also Published As

Publication number Publication date
TW538044B (en) 2003-06-21
CZ20012765A3 (cs) 2002-08-14
ATE306487T1 (de) 2005-10-15
JP3681984B2 (ja) 2005-08-10
HUP0200535A2 (hu) 2002-07-29
CA2361518A1 (en) 2000-08-03
AR029612A1 (es) 2003-07-10
NO20013751L (no) 2001-09-27
BR0007919A (pt) 2002-04-09
KR20010093308A (ko) 2001-10-27
TR200102714T2 (tr) 2002-01-21
UA74142C2 (uk) 2005-11-15
NZ513371A (en) 2003-08-29
WO2000044750A1 (en) 2000-08-03
MXPA01007851A (es) 2003-06-04
DK1150982T3 (da) 2005-12-27
NO327776B1 (no) 2009-09-21
HUP0200535A3 (en) 2002-11-28
AU2969300A (en) 2000-08-18
DE60023268D1 (de) 2006-03-02
HK1044334A1 (zh) 2002-10-18
RU2001124352A (ru) 2004-02-20
GEP20033092B (en) 2003-10-27
CN1353713A (zh) 2002-06-12
JP2002535405A (ja) 2002-10-22
IL144675A (en) 2008-11-26
IL144675A0 (en) 2002-05-23
DE60023268T2 (de) 2006-06-01
EP1150982A1 (en) 2001-11-07
NO20013751D0 (no) 2001-07-31
PL350001A1 (en) 2002-10-21
EP1150982B1 (en) 2005-10-12

Similar Documents

Publication Publication Date Title
ES2246829T3 (es) Inhibidores purinicos de cinasa 2 y de ikb-alfa dependientes de ciclina.
TW349843B (en) Substituted 1-arylpyrazoles
NO976074D0 (no) To- og treverdige småmolekylinhibitorer for selektin
LV12496A (en) Novel guanidine mimics as factor xa inhibitors
CA2160447A1 (en) Amino(thio)ether derivatives
GR3025485T3 (en) Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
DK0934301T3 (da) Aminothiophencarboxylsyreamider og anvendelse deraf som phosphodiesteraseinhibitorer
ES2189968T3 (es) Amidinofenil-pirrolidinas,-pirrolinas,e -isoxazolidinas y derivadOS DE LOS MISMOS.
GB9514518D0 (en) Guanidine salt inhibitors of NO synthase and cyclooxygenase
NO933449D0 (no) Aminderivater som korrosjonsinhibitorer
IL132773A0 (en) Guanidinylation reagents
CA2289753A1 (en) Carbocyclic nucleoside hemisulfate and its use in treating viral infections
PL326554A1 (en) Derivatives of amine and thiourea and inhibitors of nitrogen oxide synthase
BR9206776A (pt) Amino ésteres de ácido 1,3,5-triazina-2,4,6-tris-alquilaminocarboxílico agentes biocidas contendo tais ésteres e processo para prepará-los
DE69105028D1 (de) Steckschlüsselhalter.
BR9407985A (pt) Processo para a preparaçao de aminas aromáticas substituídas
TW356471B (en) Novel carbocyclic nucleoside agents useful as selective inhibitor of proinflammatory cytokines
ES514767A0 (es) Procedimiento para preparar derivados de aminoglicosidos.
MXPA02003516A (es) Clorihidrato de n-[3-[[2-(3,4-dimetoxifenil)etil]amino[propil]-4-nitrobenzamida polimorfico.
RU2002134924A (ru) Иммунодепрессант
DK0645862T3 (da) Fjederclipsholder
KR950003502U (ko) 화물차용 고정끈 호울더
ES1024132Y (es) Somier desmontable para cuna.
DK9200321U3 (da) Rundbord for fastholdelse af svinehalsben ved afsavning af riblet
KR950000634U (ko) 바이트 홀더(Bite Holder) 분해 조립용 지그(Jig)